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Premenopausal women have a lower risk of CVD and sudden death compared with men of a similar age (11) . Women and men also experience differential regulation of physiological factors that directly influence HRV and CVD, including RAS and ANS activity and responsiveness (1a, 3, 10, 17, 20, 22, 23, 28, 29, 33, 34, 37, 41, 43, 47) . The complex association among gender, RAS activity, and cardiac ANS tone may influence the risk of CVD. Thus we sought to examine the cardiac ANS response to angiotensin II (Ang II) challenge in healthy women and men of similar ages. We hypothesized that women would maintain cardiac autonomic tone, whereas men would demonstrate an unfavorable shift in cardiac sympathovagal balance in response to Ang II challenge.
METHODS
Subjects. Thirty-six (21 female, 15 male) healthy, normotensive, nonsmoking subjects were enrolled. This study was performed with the approval of the Conjoint Health Research Ethics Board of the University of Calgary and with informed, written consent of each subject. Participants underwent a detailed history and physical examination. None was on regular medications, and none used oral contraceptive medications. All women were confirmed to be premenopausal by history and measuring sex-hormone levels. To account for variation in the RAS activity during the normal menstrual cycle (10), all female subjects were studied 14 days after the 1st day of the menstrual cycle, which was verified by measuring sex-hormone levels. All subjects were counseled to adhere to a diet that maintained their normal daily caloric intake, while maintaining a high-salt state (Ͼ150 mmol/day) for 3 days prior to the study day to ensure maximal RAS suppression (34, 44) . Compliance with the high-salt diet was verified by 24-h urine collection or with a spontaneously voided morning urine sample (25) . Each study commenced at 0800 h following an overnight fast. Assessments of HRV and laboratory assays were performed in a quiet, temperature-controlled room with subjects in a supine position.
Study protocol. An 18-gauge peripheral venous cannula was inserted into each antecubital vein for infusion and blood sampling. Systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) were collected via an automated sphygmomanometer (Dinamap, GE Healthcare, Waukesha, WI) every 15 min. Subjects were infused with graded, incremental doses of Ang II (3 ng·kg Ϫ1 ·min Ϫ1 ϫ 30 min; 6 ng·kg Ϫ1 ·min Ϫ1 ϫ 30 min), followed by a 30-min recovery period.
HRV. Ambulatory ECG data were collected with a commercially available Holter monitor (SEER MC recorder, GE Healthcare). Holter data were collected continuously for 180 min (baseline, each dose of Ang II, and recovery). Frequency and time-domain measures of HRV were calculated according to standard methods guidelines (MARS version 7, GE Healthcare) (1) . Frequency domain parameters were derived using power spectral analysis, where sympathetic ANS power was represented by the low-frequency (LF; ms 2 ) band within the range of 0.04 -0.15 Hz, and parasympathetic (vagal) power was represented by the high-frequency (HF; ms 2 ) band within the range of 0.15-0.40 Hz, both of which were expressed in normalized units (nu) to account for changes in total power (1). The LF:HF ratio component was calculated by comparing crude LF and HF parameters, representing total sympathovagal balance. Time-domain measures included the SD of all normal R-R-wave intervals [SDNN (ms)], SD of the average normal R-R-wave intervals [SDANN (ms)], and percentage of normal waves differing Ն50 ms compared with the wave prior (pNN50%) (1) .
Analytical methods. Plasma renin activity (PRA) was determined by the quantification of plasma Ang I, a surrogate measure of PRA, by radioimmunoassay (PRA 125I, DiaSorin, Stillwater, MN). Ang II plasma levels were measured by standard laboratory immunoassay techniques (Quest Diagnostics, San Juan Capistrano, CA). Serum aldosterone levels were determined by radioimmunoassay techniques (Aldosterone Coat-A-Count kit, InterMedico Diagnostic Products, Markham, Ontario, Canada). Serum creatinine, cholesterol, and triglyceride (TG) assays were quantified by enzymatic colorimetric assay techniques (Roche/Hitachi Creatinine Plus; CHOD-PAP, HDL-C Plus, and TG GPO-PAP kits, Roche Diagnostics, Indianapolis, IN, respectively).
Statistical analysis. Values are presented as mean Ϯ SE, unless otherwise indicated. The primary analysis evaluated the associations between HRV (LF, HF, LF:HF, SDNN, SDANN, pNN50%) at baseline and HRV responses to 30 and 60 min of graded Ang II infusion. Data were assessed for normality, and natural logarithms were applied to non-normally distributed values, including the absolute LF and HF domain measurements (ms 2 ). Between-group baseline differences were determined using Student's t-test, whereas within-subject differences in the longitudinal responses to the acute Ang II infusion were determined by paired t-test. Multivariate linear regression analyses were performed to assess the contributory effects of clinical variables in determining specific sympathetic and vagal responses [mean change (⌬)LF, ⌬HF, and ⌬LF:HF]. The following variables were considered in the backward, step-wise models: gender, age, body mass index (BMI), baseline HRV, MAP, baseline PRA. A secondary analysis also modeled in relevant CVD risk factors, including HDL cholesterol, LDL cholesterol, TGs, and high-sensitivity C-reactive protein (hs-CRP) (19) , as well as baseline norepinephrine (NE) and baseline epinephrine (Epi). Separate univariate analyses tested the associations between relevant gender-specific sex hormones and the HRV responses to Ang II challenge within each gender group. Statistical analyses were performed using SPSS (version 19, IBM, Armonk, NY). No adjustment for multiple comparisons was undertaken, given that this was an exploratory study. Two-tailed P values Ͻ0.05 were considered to be statistically significant.
RESULTS
Baseline characteristics. Baseline characteristics of subjects are summarized in Table 1 . All were normotensive, nonobese, nondiabetic, and had normal kidney function. SBP and DBP did not significantly differ between each gender, although female SBP was slightly lower compared with male (114 Ϯ 3 mmHg vs. 120 Ϯ 4 mmHg). Women displayed lower TG levels and higher HDL blood plasma concentrations compared with men. Lower levels of circulating components of the RAS were also observed in women compared with men, with the exception of endogenous Ang II. Women also had lower levels of serum creatinine than did men, likely a reflection of differences in muscle mass. Women exhibited lower baseline sympathetic activity (LF nu), higher vagal activity (HF nu), and significantly lower mean SDNN values compared with men; however, all frequency and time-domain HRV parameters were within the normal range for both genders (5, 38) .
Cardiac autonomic response to Ang II challenge. Subjects' cardiac autonomic responses to graded Ang II challenge are outlined in Table 2 . In response to 30 min of 3 ng·kg Ϫ1 ·min
Ϫ1
Ang II infusion, women maintained cardiac autonomic tone (⌬LF:HF 0.5 Ϯ 0.3; P ϭ 0.8 vs. baseline), whereas men displayed a trend toward an unfavorable shift in cardiac autonomic tone (⌬LF:HF 1.8 Ϯ 0.6; P ϭ 0.4 vs. baseline), which was statistically different from women (P ϭ 0.04; Fig. 1 ). Distinct gender differences were observed in the cardiac autonomic responses to the higher dose of Ang II. Whereas overall sympathovagal balance was largely maintained in females (⌬LF:HF 0.5 Ϯ 0.4; P ϭ 0.4 vs. baseline), male subjects experienced a further unfavorable shift in cardiac ANS activity (⌬LF:HF 2.6 Ϯ 0.2, P ϭ 0.01, vs. baseline; P ϭ 0.02 vs. female response; Fig. 1 ). This imbalance in sympathovagal tone appeared to be driven largely by a withdrawal in cardioprotective vagal activity in response to Ang II challenge (⌬HF nu, Ϫ5.8 Ϯ 2.9, P ϭ 0.01, vs. baseline; P ϭ 0.006 vs. female response) rather than an increase in sympathetic activity (⌬LF nu, Ϫ4.5 Ϯ 5.7, P ϭ 0.3, vs. baseline; P ϭ 0.5 vs. female All data are expressed as mean Ϯ SE. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HDL and LDL (cholesterol); NE, norepinephrine; Epi, epinephrine; hs-CRP, high-sensitivity C-reactive protein; PRA, plasma renin activity; Ang II, angiotensin II; Aldo, aldosterone; LF, low-frequency; ln, natural logarithms; HF, high-frequency; nu, normalized units; SDNN, SD of the normal R-R wave; SDANN, SD of the average normal R-R wave; pNN50%, percentage of normal waves that differ Ն50 ms compared with the wave directly prior. *P Ͻ 0.01 compared with females; †P Ͻ 0.05 compared with females. response; Fig. 2) . A continued trend toward higher values of each of the time-domain HRV measurements was observed at time 60 of the Ang II challenge, although only the increase in SDANN in women reached statistical significance (P ϭ 0.02). No differences in the time-domain HRV measures in response to the higher dose of Ang II were observed in women vs. men (SDNN, P ϭ 0.2; SDANN, P ϭ 0.4; pNN50%, P ϭ 0.3).
Hemodynamic and RAS response to Ang II challenge. Subjects' responses to graded Ang II challenge are outlined in Table 2 . All subjects demonstrated the anticipated, significant increase in BP in response to Ang II challenge, although no difference between genders was observed (Table 2; Fig. 3 ). In keeping with known regulatory control of the RAS, PRA decreased, and aldosterone increased throughout the Ang II challenge in all subjects, with men demonstrating higher baseline activity and greater PRA sensitivity to Ang II (Table 2 ; Fig. 4) .
Multivariate linear regression analysis. Following multivariate analysis, gender remained a predictor of the LF:HF response to Ang II at both time 30 (P ϭ 0.1) and time 60 (P ϭ 0.1). Inclusion of other relevant CVD risk factors, such as HDL, LDL, and hs-CRP (19) , in the analysis yielded similar results (time 30, P ϭ 0.1; time 60, P ϭ 0.08). Moreover, whereas measures of circulating catecholamines are not always reflective of cardiac ANS activity (4), gender was a significant predictor of the sympathovagal responses to Ang II challenge after adjustment for baseline NE and Epi (⌬LF:HF time 30, P ϭ 0.2; time 60, P ϭ 0.006). The overall BP, PRA, and aldosterone responses in males and females did not differ statistically and were not significantly associated with sex hormones in multivariate analyses. Testosterone levels of male subjects, although not associated with any frequency domain parameters (14) , were weakly correlated with improved timedomain measures of HRV response at time 60, namely SDNN (r ϭ 0.54; P ϭ 0.048) and SDANN (r ϭ 0.66; P ϭ 0.01).
DISCUSSION
This is the first study to examine the impact of gender on the resting cardiac ANS response to Ang II challenge in healthy, middle-aged men and women. The rationale for the study was twofold. First, significant gender differences exist in CVD risk, and cardiac ANS modulation exists between women and men (1a, 23, 28, 29, 33, 41, 50a). Furthermore, the RAS has been implicated in CVD progression in both sexes (7) . Second, the role of the RAS-activity of which is upregulated in patients at high CVD risk-in controlling cardiac ANS function is unclear. We thereby hypothesized that if a gender-mediated difference in cardiac ANS modulation exists, it would be possible to observe this phenomenon by analyzing baseline HRV and HRV response during a graded Ang II infusion in healthy female and male subjects. The key findings in this study are that in response to acute, 60-min Ang II challenge, women maintained overall cardiac sympathovagal balance, whereas men of similar age experienced an unfavorable shift in sympathovagal balance, largely resulting from a withdrawal of vagal input.
Influence of the RAS on cardiac autonomic tone.
It is well accepted that CVD and sudden cardiac death are the major contributors to mortality within populations, which characteristically display upregulation of the RAS, including those with congestive with heart failure (40), myocardial infarction (5, 27, 45) , and chronic kidney disease (9, 36, 42) . Previous studies have supported a link between RAS activity and cardiac ANS tone. For instance, the blunted HRV measures observed in a recent mouse model of obesity are improved by inhibition of ACE (21) . Furthermore, the AA genotype of A 1166C polymorphism in the angiotensin type 1 (AT1) receptor gene may be associated with a decline in cardiac sympathetic tone during the head-up tilt test in patients with neuro-mediated syncope (35) . This underscores the relationship between the RAS and cardiac ANS tone. Furthermore, improvement in HRV following pharmacological interruption of the RAS has been observed in some human studies (6, 12, 21) , and any discrepancies in the effect of ACE inhibition and angiotensin receptor blockade on cardiac ANS tone are attributed to differences in medication dosage, patient populations, and concomitant use of other drugs that may impact HRV (12) . Although these investigations provide good evidence to link the RAS and HRV, they did not differentiate between genders when analyzing their outcomes, regardless of the fact that female sex has been associated with more favorable RAS activity (17, 20, 34, 37, 47) , as well as an improved cardiac autonomic profile attributed to amplified vagal input (1a, 23, 28, 29, 33, 41) . Although we are not aware of any studies directly examining the interaction between the RAS upregulation and HRV response during Ang II challenge in healthy humans, previous animal and human investigations support a sexual dimorphism in regards to the control of cardiac ANS tone.
Female sex confers a cardioprotective advantage during modulation of cardiac autonomic tone in response to RAS upregulation. Similar to our data, other investigators have found that women demonstrate exaggerated cardioprotective vagal input, whereas men commonly exhibit higher sympathetic activity, both at baseline and in response to external stressors (1a, 23, 28, 29, 33, 41) . Huikuri et al. (23) demonstrated that in response to an abrupt rise in BP with a Valsalva maneuver, there is greater cardioprotective vagal modulation in healthy females compared with male subjects, implying that the similar changes observed in our subjects may have been due to the acute rise in BP rather than the direct response to Ang II. However, a study of healthy women and men showed no gender differences in baroreflex sensitivity to a phenylephrine infusion, suggesting that the results observed in our study are likely, directly due to the effects of exogenous Ang II. Withdrawal of vagal activity is related to a greater susceptibility to heart disease, as well adverse cardiac events (12, 19a) . It is unclear, however, that the difference in behavior of the cardiac ANS in women and men substantially contributes to the large gender differential in morbidity and mortality of heart disease, which cannot be explained by the presently known standard risk factors (9) . We have demonstrated that healthy, premenopausal, female subjects have a greater capability to maintain cardioprotective vagal tone in response to a stressor, such as Ang II, when compared with men of similar age. Our findings are supported by the observation that rates of coronary heart disease in women increase in the fifth decade of life, which suggests that the maintenance of vagal tone during stress in younger women is a protective factor, which is lost near menopause (11, 29, 33) , although this remains speculative given the limited age range of our study subjects.
Potential modifiers of the gender-mediated cardiac autonomic response during RAS upregulation. Sex differences in RAS activity have been well documented (17, 20, 34, 37, 43, 47). Miller et al. (34) observed that healthy women achieved significantly reduced Ang II sensitivity compared with men at lower dosages of AT1 receptor blocker. Females showed no pressor response after 4 wk of treatment with 75 mg/day irbesartan, whereas men continued to exhibit a pressor response following 4 wk of 150 mg/day. Whereas the exact mechanism for these gender-mediated differences in sensitivity remains elusive, potential differences in Ang II metabolism, activation of AT1 receptors, and signal transduction pathways may account for some of the discrepancies observed (47) . Endogenous female sex hormones have been implicated as protective; certainly, estrogen has been shown to have vasoprotective effects via downregulation of the AT1 receptor (20, 37) , and surgical menopause results in a decrease in cardiac vagal modulation (33) . Whereas we did not find any relationship between estrogen and any measure of HRV, this may simply be a reflection of the limited variation in estrogen levels in our female subjects, due to our careful consideration in timing study days at the same point of the menstrual cycle to minimize the influence of the menstrual cycle on both the cardiac ANS (33) and the RAS (10) . Testosterone levels of male subjects, although not associated with any frequency domain parameters, were weakly correlated with time-domain measures of HRV response, as has been suggested previously (14) . Further studies are required to investigate the importance of this finding in regards to gender-related mechanisms controlling the differences in cardiovascular risk within the general population.
Next, wide variation was observed in baseline Epi levels of male subjects enrolled in this study. A correlation between SBP and Epi levels in men in the supine position has been shown previously (26) ; however, all of our male subjects displayed very little variation in baseline SBP measurements. Glucose metabolism and body weight have also been suggested to be involved with the regulation of male Epi levels (15, 49) ; however, all subjects in this study were nondiabetic and nonobese. Finally, testosterone has also been shown to influence plasma Epi concentration (15) , although all male subjects had similar testosterone measurements with limited variability. In addition, all subjects in this study demonstrated Epi values within the normal range, as defined by normal ranges for the assay. Moreover, whereas measures of circulating catecholamines are not always reflective of cardiac ANS activity (4), gender remained a predictor of the cardiac sympathovagal response to Ang II challenge after adjustment for baseline NE and Epi. Lastly, hs-CRP has been shown to be inversely correlated with HRV (19), which we did not observe; however, as the female subjects in our study had higher hs-CRP levels, this would have only biased our results toward the null.
Strengths and limitations. Previous reports have indicated a variety of factors that may influence modulation of cardiac autonomic tone in both genders. Notably, hyperinsulinemia, the typical feature of insulin resistance, has a stimulatory influence on the SNS and is associated with a hindrance of HRV (16) . Furthermore, both hyperglycemia and increased insulin levels are associated with increased RAS activity (39) . However, our exclusion criteria ensured that all subjects were free of diabetes and had fasting insulin and glucose levels within the normal ranges. Obesity can also adversely influence HRV (16, 46) , and we have shown previously that increased BMI is associated with increased activation of the RAS (2). Women and men included within this study were nonobese, and all had similar measurements of BMI. Abnormal kidney function is associated with both upregulated RAS activity and altered cardiac autonomic tone (5, 7, 9, 36, 40, 42, 45) . As such, all subjects in this study were required to have normal kidney function, which was determined by blood work and urinalysis. The high-salt balance protocol, a state reflective of the typical Western diet (18, 50) , deserves comment. A high-salt diet results in maximal, systemic RAS suppression (34, 44) which allowed us to study our subjects in a similar state of RAS activation, resulting in meaningful comparisons of the responses with endogenous Ang II between genders. In a study of 36 healthy women, low dietary-salt intake was associated with a decrease in both LF and HF, with an overall increase in the LF:HF ratio, whereas a high-salt diet did not alter the cardiac ANS activity compared with baseline (32) . As such, we do not believe that the high-salt intake modified baseline measures of HRV compared with their usual state in the female subjects in our study. Differences in HRV, both at baseline and in response to stressors, between salt-sensitive (SS) and salt-resistant (SR), normotensive men, have been described (8, 13) , with SS, normotensive men showing significantly lower HRV at baseline compared with their SR counterparts and a greater depressive HF (vagal) response during stress. Whereas we are not aware of the SS or SR status of our male subjects, this would only bias our results toward the null hypothesis, and thus our determination of the effect of Ang II challenge may, in reality, be an underestimation of the true effect. However, whether the effects observed in our study would remain if subjects' salt intake were in keeping with the World Health Organization's recommendation of 100 mEq/day (50) is beyond the scope of this study and merits further investigation. Lastly, the gold standard of HRV measurement is with a 24-h Holter ECG monitor to account for changes in sympathetic and vagal ANS tone throughout sleep and wake cycles. However, many studies routinely use shortterm ECG recordings, as the accuracy of these more practical HRV analyses has been substantiated against long-term measurements (4). This study included a 180-min period of Holter ECG monitoring in a calm, temperature-controlled room, diminishing the effect of heavy respiratory, parasympathetic activity, which has been suggested to alter short-term HRV analysis (19a) . The short-term nature of this study precludes the extrapolation of our observations to a state of chronic upregulation of the RAS, as is commonly seen in many disease states. Overall, our study subjects represented a homogenous sample of healthy humans of similar age and ethnicity, thus potentially limiting generalizability but allowing us to focus on the impact of gender on the cardiac ANS response to Ang II challenge in the absence of confounding factors.
Conclusion. This study demonstrated the influence of gender on the cardiac ANS tone response to acute Ang II challenge in healthy human subjects. Specifically, women maintain cardiac ANS balance during acute Ang II challenge, whereas men experience an unfavorable shift in cardiac sympathovagal tone, largely driven by profound withdrawl of vagal input. To date, the deleterious hemodynamic and mitogenic effects of Ang II are well known; however, the gender-mediated differences in the cardiac ANS response to Ang II, observed in our study, suggest a possible mechanism leading to the discrepancies in CVD outcomes observed in women and men experiencing hyperactivity of the RAS. Further studies are required to confirm these hypotheses in both healthy and diseased populations. 
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